POLYMORPHIC MODIFICATION IN N- {5- 3- (THIOFEN-2-CARBONYL) -PYRAZOLO 1,5-a PYRIMIDIN-7-IL -2-FLUOR-Phenyl} -N-METHYL-ACETAMIDE (OPTIONS), CONTAINING ITS PHARMACEUTICAL COMPOSITION (OPTIONS), MEDICINAL PRODUCT, METHOD FOR OBTAINING THE SPECIFIED POLYMORPHIC MODIFICATION IN (OPTIONS) AND METHOD FOR TREATING AND / OR PREVENTION OF NERVOUS DISEASES

摘要

1. Polymorphic modification of N- {5- [3- (thiophen-2-carbonyl) -pyrazolo [1,5-a] pyrimidin-7-yl] -2-fluoro-phenyl} -N-methyl-acetamide, characterized by powder X-ray diffractometry curve having specific peaks at 20 = 7.1 ° (± 0.1 °) and 21.4 ° (± 0.1 °). ! 2. The polymorphic modification according to claim 1, characterized by a curve of powder x-ray diffractometry having specific peaks at 2θ = 7.1 ° (± 0.1 °), 11.8 ° (± 0.1 °), 12.3 ° ( ± 0.1 °), 12.6 ° (± 0.1 °), 13.7 ° (± 0.1 °), 14.7 ° (± 0.1 °), 15.5 ° (± 0 , 1 °), 19.0 ° (± 0.1 °), 20.8 ° (± 0.1 °), 21.4 ° (± 0.1 °), 22.0 ° (± 0.1 °), 22.3 ° (± 0.1 °), 22.6 ° (± 0.1 °), 23.4 ° (± 0.1 °), 23.9 ° (± 0.1 °) , 25.6 ° (± 0.1 °), 26.3 ° (± 0.1 °), 27.1 ° (± 0.1 °), 27.8 ° (± 0.1 °), 31 , 8 ° (± 0.1 °) and 36.5 ° (± 0.1 °). ! 3. Polymorphic modification of N- {5- [3- (thiophen-2-carbonyl) -pyrazolo [1,5-a] pyrimidin-7-yl] -2-fluoro-phenyl} -N-methyl-acetamide, characterized by Fourier transform Raman spectrum having characteristic signals at 3107 cm-1, 1605 cm-1, 1593 cm-1, 1538 cm-1, 1336 cm-1 and 102 cm-1. ! 4. Polymorphic modification of N- {5- [3- (thiophen-2-carbonyl) -pyrazolo [1,5-a] pyrimidin-7-yl] -2-fluoro-phenyl} -N-methyl-acetamide, characterized by differential scanning calorimetry having a melting peak of about 158 ° C. ! 5. The method of producing the polymorphic modification according to any one of claims 1 to 4, in which the polymorphic modification A of N- {5- [3- (thiophen-2-carbonyl) -pyrazolo [1,5-a] pyrimidin-7-yl is suspended ] -2-fluoro-phenyl} -N-methyl-acetamide at room temperature in a solvent selected from the group consisting of C1-C6 aliphatic alcohols, C1-C6 aliphatic ketones, C1-C4 alkyl esters of C1-C4 aliphatic acids, C4-C5 saturated cyclic ethers , C1-C6 aliphatic nitriles, aromatic hydrocarbons and water, and mixtures selected from the group consisting of C1-C6 aliphatic alcohol and C1-C6 aliphatic organic acid, water and C1-C6 aliphatic alcohol,